CLINICAL TRIAL SUMMARY

MDACC Study No:CERN08-02 (clinicaltrials.gov NCT No: NCT00826241)
Title:A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Principal Investigator:Mark R. Gilbert
Treatment Agent:Lapatinib; Temozolomide
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if lapatinib when given in
combination with temozolomide can help to control ependymoma that has come back
after treatment. The safety of this combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase II
Treatment Agents:Lapatinib
Temozolomide
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Collaborative Ependymoma Research Network
Return Visit:Every 8 weeks
Home Care:Patient will take temozolomide and lapatinib orally at home


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Mark R. Gilbert
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults